JPMorgan Chase Gave Positive Clues Before Its Earnings Beat
However, the longer-term picture for the bank giant's shares is clouded by questions about volume and buyers' commitment to the stock.
The Bulls Are Not Going Away Without a Fight
Monday's intraday reversal hit leading stocks the hardest, but bears need to gain some downside momentum to prove they can be taken seriously.
Jim Cramer: If You're Buying These Stocks, You Need to Rethink Your Approach
Few who are buying these names on the Robintrack leaderboard are looking at the side that really matters.
Think Like an Owner, Not a Trader
Don't be dazed by star stocks like Tesla, and instead stop and think: What do you really get when you buy stock in a company?
Netflix Reports Earnings on Thursday: 6 Important Things to Watch
Along with paid subscriber numbers, keep an eye on Netflix's second-half and regional commentary, as well as its free cash flow guidance.
Which Door Did the Market Choose on Monday?
Let's look at the reversal and see which path we're on now.
Textbook Case of Reversal Action Has Finally Hit
The key issue for reactive traders is to spot an intraday reversal and a poor close -- that will be the primary tip-off that further problems await.
Gilead Sciences Is Set to Break Out: How to Play It
The stock is trading above the 50-day and the 200-day moving averages.
GlaxoSmithKline Is Offering Subtle Clues for Investors
Let's check out the charts of this healthcare stock.
Jim Cramer: How Do You Refute These Market Gains?
This is pretty much exactly what you get when you have so much positive research.